Semaglutide vs survodutide: evidence, cost, and legality

Which is better, semaglutide or survodutide?

The only direct trial was short (16 weeks) and phase 2: survodutide matched semaglutide 1 mg on HbA1c at low dose and beat it on weight at 1.8 mg and above, with more gastrointestinal adverse events. Semaglutide has phase 3 and cardiovascular outcomes evidence, an FDA label, and lawful access. Survodutide's distinctive signal is liver disease (MASH), which matters for trial choices but not for anyone seeking treatment today. [1] [2] [3] [4] [5]

How do semaglutide and survodutide compare?

Semaglutide and Survodutide compared by dimension
Dimension	SemaglutideFavored	Survodutide
Head-to-head evidence [1]	Semaglutide up to 1 mg weekly (open label): HbA1c fell 1.47 points and weight 5.3% at 16 weeks.	Survodutide 0.9 mg weekly lowered HbA1c 1.46 points, similar to semaglutide; doses of 1.8 mg weekly and above lowered weight more than semaglutide, up to 8.7% at 16 weeks.
Note: Phase 2 trial of 413 adults with type 2 diabetes on metformin; the semaglutide arm was open label while survodutide and placebo were blinded.
Mechanism [4] [6]	Selective GLP-1 receptor agonist.	Dual glucagon and GLP-1 receptor agonist; glucagon activity raises energy expenditure and liver fat oxidation.
Phase 3 weight loss [2] [4]	14.9% versus 2.4% on placebo at 68 weeks (STEP 1, 1,961 adults, 2.4 mg).	12.2% (3.6 mg) and 13.0% (6.0 mg) versus 5.4% on placebo at 76 weeks (SYNCHRONIZE-1, 725 adults).
Note: Separate trials with different estimands and durations; not a direct comparison.
Liver disease evidence [5] [6]	FDA granted accelerated approval of Wegovy for MASH with moderate to advanced fibrosis in 2025.	Phase 2 MASH trial (293 adults): improvement without worsening fibrosis in 47% to 62% versus 14% on placebo at 48 weeks.
Cardiovascular outcomes [3] [4] [7]	SELECT hazard ratio 0.80 in obesity with cardiovascular disease; SUSTAIN-6 hazard ratio 0.74 in type 2 diabetes.	No outcomes trial has reported.
Tolerability [1] [4]	Adverse events in 52.0% on semaglutide 1 mg in the direct trial.	Adverse events in 77.8% on survodutide in the direct trial, mainly gastrointestinal; gastrointestinal symptoms in 80.9% to 89.7% versus 47.9% on placebo in SYNCHRONIZE-1.
Regulatory status [6] [8] [9]	FDA approved (Ozempic, Rybelsus, Wegovy). Shortage-based compounding ended in 2025.	Investigational; not approved by FDA or any other regulator, not on the 503A bulks list, and cannot lawfully be compounded.
WADA status [10]	Not on the WADA Prohibited List.	Prohibited under section S0 (non-approved substances).

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Semaglutide and Survodutide: grade, status, and cost
Attribute	Semaglutide	Survodutide
Class	GLP-1 receptor agonist (31 amino acid analog of human GLP-1, acylated for once weekly dosing)	Investigational dual agonist of the glucagon and GLP-1 receptors (acylated peptide, once weekly)
What it is	FDA approved GLP-1 agonist with about 15% average weight loss in a 68 week RCT and proven cardiovascular benefit.	Investigational glucagon/GLP-1 dual agonist: 13% weight loss at 76 weeks in phase 3 and strong liver (MASH) data, but not FDA approved.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: Not eligible for compounding
Compounding	FDA approved products (Ozempic 2017, Rybelsus 2019, Wegovy 2021). FDA removed semaglutide from the drug shortage list on February 21, 2025; compounding by 503A pharmacies had to stop by April 22, 2025 and by 503B outsourcing facilities by May 22, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit GLP-1 products and salt forms (semaglutide sodium, semaglutide acetate) that are not the approved active ingredient. On April 30, 2026 FDA proposed not to include semaglutide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms.	Not FDA approved and not approved by any other regulator as of the last verification date. Because survodutide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded by 503A pharmacies or 503B outsourcing facilities. Any product sold as survodutide outside a clinical trial is an unapproved drug that has not been evaluated for identity, purity, or dose.
WADA	WADA: Not WADA prohibited	WADA: WADA prohibited
Routes	Subcutaneous injection once weekly (Ozempic, Wegovy), Oral tablet once daily (Wegovy tablets, Ozempic tablets, Rybelsus)	Subcutaneous injection once weekly (clinical trials only)
Typical cost	Manufacturer list price is 1,349.02 USD per month for Wegovy and 1,027.51 USD for Ozempic (checked 2026-09-22), falling to 675 USD for both on January 1, 2027. Manufacturer self-pay prices run 149 to 499 USD per month by product and dose, with the Wegovy pen at 349 USD. With commercial insurance the manufacturer savings offer can bring a covered prescription to 25 USD per month, and eligible Medicare Part D enrollees pay 50 USD per month for Wegovy under the Medicare GLP-1 Bridge (July 2026 to December 2027). A 2024 study found compounded semaglutide at a median 231 USD for the first month during the shortage; compounding is now limited to patient specific needs.	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 27, 2026	Sep 27, 2026

Has semaglutide been tested directly against survodutide?

Direct comparisons of Semaglutide and Survodutide
Study	Design and population	Outcome	Grade
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes2024 PMID 38095657	Randomized, double blind, placebo controlled phase 2 trial with an open label semaglutide arm, 16 weeksn = 413 Adults with type 2 diabetes on metformin, HbA1c 7.0% to 10.0%, BMI 25 to 50	HbA1c change minus 1.46 points with survodutide 0.9 mg versus minus 1.47 with semaglutide 1 mg; weight change up to minus 8.7% with survodutide versus minus 5.3% with semaglutide; adverse events 77.8% versus 52.0%	Evidence: Human RCT evidence

What do semaglutide and survodutide cost?

Typical cost of Semaglutide and Survodutide
Dimension	Semaglutide	Survodutide
Typical cost	$149 to $1,349 per month	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	Semaglutide price by channel	Price index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Does survodutide cause more weight loss than semaglutide?

In a 16 week phase 2 diabetes trial, survodutide at 1.8 mg weekly and above lowered weight more than semaglutide 1 mg (up to 8.7% versus 5.3%). No trial has compared it with the 2.4 mg obesity dose of semaglutide. [1]

Is survodutide approved?

No. It is investigational, cannot lawfully be compounded in the United States, and is only available inside registered clinical trials. [4] [9]

Which is better for fatty liver disease?

Semaglutide is the one that is approved: FDA granted Wegovy accelerated approval for MASH with fibrosis in 2025. Survodutide has strong phase 2 liver data (MASH improvement in up to 62% versus 14% on placebo) but no approval. [5] [6]

Are athletes allowed to use either one?

Semaglutide is not on the WADA Prohibited List. Survodutide is prohibited under section S0 because no regulator has approved it. [10]

Conditions studied

From the blog

Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Semaglutide vs survodutide: evidence, cost, and legality. https://peptideagent.ai/compare/semaglutide-vs-survodutide
HTML link: <a href="https://peptideagent.ai/compare/semaglutide-vs-survodutide">Semaglutide vs survodutide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Semaglutide vs survodutide

The short answer